Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1995-06-07
1998-11-17
Dees, Jose G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
A61K 3156
Patent
active
058377000
ABSTRACT:
Sex steroid precursors such as dehydroepiandrosterone and dehydroepiandrosterone sulphate, and compounds converted in vivo to either of the foregoing, are utilized for the treatment and/or prevention of vaginal atrophy, hypogonadism, diminished libido, osteoporosis, urinary incontinence, ovarian cancer, uterine cancer, skin atrophy, for contraception, and, in combination with an estrogen and/or progestin, for the treatment of menopause. The precursors may be formulated for percutaneous or transmucosal administration. Gels, solutions, lotions, creams, ointments and transdermal patches for the administration of these precursors are provided, as are certain pharmaceutical compositions and kits which can be used for the prevention and treatment of a wide variety of conditions related to decreased secretion of sex steroid precursors by the adrenals.
REFERENCES:
patent: 3472931 (1969-10-01), Stoughton
patent: 3551554 (1970-12-01), Herschler
patent: 3742951 (1973-07-01), Zaffaroni
patent: 3797494 (1974-03-01), Zaffaroni
patent: 3989816 (1976-11-01), Jagannath
patent: 4006218 (1977-02-01), Tibor
patent: 4213978 (1980-07-01), Bodor
patent: 4405616 (1983-09-01), Rajadhyaksha
patent: 4425339 (1984-01-01), Pitchford
patent: 4496556 (1985-01-01), Orentreich
patent: 4518595 (1985-05-01), Coleman
patent: 4542129 (1985-09-01), Orentreich
patent: 4568343 (1986-02-01), Leeper
patent: 4624665 (1986-11-01), Nuwayser
patent: 4666441 (1987-05-01), Andriola
patent: 4812447 (1989-03-01), Roberts
patent: 4835147 (1989-05-01), Roberts
patent: 4956355 (1990-09-01), Prendergast
patent: 4978532 (1990-12-01), El-Rashidy
patent: 5047244 (1991-09-01), Sanvordeker et al.
patent: 5051260 (1991-09-01), Chess
patent: 5064654 (1991-11-01), Berner
patent: 5071644 (1991-12-01), Viegas
patent: 5071657 (1991-12-01), Oloff
patent: 5116828 (1992-05-01), Miura et al.
patent: 5135480 (1992-08-01), Bannon
patent: 5154922 (1992-10-01), Govil
patent: 5162037 (1992-11-01), Whitson
patent: 5362720 (1994-11-01), Labrie
Marshall DH; Crilly R; Nordin BED (1978) The relation between plasma androstenedione and oestrone levels in untreated and corticosteroid-treated post-menopausal women. Clin.Endocrinology. 9:407-412.
Migeon CJ; Keller AR; Lawrence B; Shepard TH (1957) Dehydreopiandrosterone and androsterone levels in human plasma effect of age and sex; day-to-day and diurnal variations. J. Clin. Endocr.Metab. 17:1051-1062.
Need, A.G.; Horowitz, M.; Moris, H.A.; Walker, C.J.; Nordin, B.E.C. (1987) Effects of nadrolone therapy on forearm bone mineral contant in osteoporosis. Clin. Orthop. 225:273.
Nieschlag E; Lammers U; Freischem CW; Langer K; Wickings EJ (1982) Reproductive functions in young fathers and grandfathers. J.Clin.Endocr.Metab. 55:676-681.
Nordin BED; Aaron J; Speed R; Crilly RG (1981) Bone formation and resorption as the determinants of trabecular bone volume in postmenopausal osteoporosis. The Lancet. Aug.: 277-279.
Nordin, B.E.C.; Robertson, A.; Seamark, R.F.; Bridges, A.; Philcox, J.C.; Need, A.G.; Horowitz, M.; Morris, H. A.; Deam, S. (1985) The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. J.Clin.Endocr. Metab. 60:651-657.
Odell, W.D.; Swerdloff, R.S. (1976) Male hypogonadism. West. J. Med. 124:446-475.
Parish EJ; Chitrakorn S (1985) Benzotriazole-mediated selective chromium(vi) oxidations. Synth. Commun. 15:393-399.
Parker C.R.; Simpson, E. R.; Bilheimer, D.W.; Leveno, K.; Carr, B. R.; MacDonald P.C. (1980) Inverse relation between low-density lipoprotein-cholesterol and dehydroisoandrosterone sulfate in human fetal plasma. Science. 208:512-514.
Pettit GR; Kamano Y; Drasar P; Inoue M; Knight JC (1987) Synthesis of bufalitoxin and bufotoxin. J.Org.Chem. 52:3573-3578.
Pinelli A; Nair PP (1969) Gas-liquid chromatographic separation of steroids and their derivatives on a dual component column of high thermal stability. J. Chromatogr. 43:223-228.
Pohlmann JLW; Elser W; Boyd PR (1971) Structure dependence of cholesteric mesophases II. Mol.Cryst.Liquid Cryst. 13:243-254.
Poulin, R.; Baker, D.; Labrie, F. (1988) Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res. Treatm. 12:213-225.
Poulin, R.; Labrie, F. (1986) Stimulation of cell proliferation and estrogenic response by adrenal C19-.increment.5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res. 46:4933-4937.
Reber F; Reichstein T (1945) d-galaktose-3-methylather. Helv. Chim. Acta. 28:1164-1176.
Riggs, B. L.; Wahner, H. W.; Dunn, W. L.; Mazess, R. B.; Offord, K. P.; Melton, L. J. (1987) Differential changes in bone mineral density of the appendicular and axial skeleton with aging. J.Clin.Invest. 67:328-335.
Riva S; Bovara R; Ottolina G; Secundo F; Carrea G (1989) Regioselective acylation of bile acid derivatives with candida cylindracca lipase in anhydrous benzene. J. Org. Chem. 54:3161-3164.
Rose DP; Stauber P; Theil A; Crowley JJ; Milbrath JR (1977) Plasma dehydroepiandrosterone sulfate, androstenedione and cortisol, and urinary free cortisol excretion in breast cancer. Europ.J.Cancer. 13:43-47.
Schaefer (1982) (Schaefer, Zesch and Stuttgen, eds), Springer-Verlag: Berlin, Heidelberg, New York. 896.
Schwartz, A. G. (1979) Inhibition of spontaneous breast cancer formation in female C3H (Avy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res. 39:1129-1132.
Seevers RH; Groziak MP; Weichert JP; Schwendner SW; Szabo SM; Longino MA; Counsell RE (1982) Potential tumor- or organ-imaging agents. 23. Sterol esters of iopanoic acid. J.Med.Chem. 25:1500-1503.
Silverberg M; Silberberg R (1971) Steroid hormones and bone. In:The biochemistry and physiology of bone (Bourne GH, ed), Academic Press: New York. Vol. II, 2nd ed.: pp. 401-484.
Sledge, G. W.; McGuire, W. L. (1983) Steroid hormone receptors in human breast cancer. Adv.Cancer Res. 38:61-75.
Smith, D. C.; Walker, M. S. (1977) Changes in plasma steroids and bone density in Klinefelter's syndrome. Calcif. Tissue Res. 22:225-228.
Thijssen et al. (1975) Androgen in postmenopausal breast cancer: Excretion, production and interaction with estrogens.J.Steroid Biochem. 6:729-734.
Urist, M. R.; Vincent, P. J. (1961) The excretion of various fractions of the 17-ketosteroids in the urine in women with postmenopausal or senile osteoporosis. J. Clin. Orthop. 18:199-208.
Verhas, M.; Schoutens, A.; L'Hermite-Baleriaux, M.; Dourov, N.; Verschaeren, A.; Mone, M.; Heilporn, A. (1986) The effect of orchidectomy on bone metabolism in aging rats. Calif. Tissue Res. 39:74-77.
Vermeulen A; Deslypere JP; Schelfhout W; Verdonck L; Rubens R (1982) Adrenocortical function in old age: response to acute adrenocorticotropin stimulation. J. Clin. Endocrinol.Metab. 54:187-191.
Vermeulen A; Verdonck L (1976) Radioimmunoassay of 17.beta.-hydroxy-5.alpha.-androstan-3-ones,4-androstene-3,17-dione,dehydro epiandrosterone. 17-hydroxyprogesterone and progesterone and its application to human male plasma. J. Steroid Biochem. 10:1-10.
Wang DY; Bulbrook RD; Herian M; Hayward JL (1974) Studies on the sulphate esters of dehydroepiandrosterone and androsterone in the blood of women with breast cancer. Europ.J.Cancer. 10:477-482.
Weisz I (1986) Selective reactions of some steroids with diethyl dicarbonate. Arch. Pharm. (Weinheim, Ger.). 319:952-953.
Wink CS; Felts WJL (1980) Effects of castration on the bone structure of male rats: a model of osteoporosis. Calcif. Tissue Int. 32:77-82.
Wittliff, J.L. (1984) Steroid-hormone receptors in breast cancer. Cancer. 53:630-643.
Yamashita H; Kurosawa Y (1975) Production of 16.alpha.-hydroxydehydroepiandrosterone. Agric. Biol. Chem. 39:2243-2244.
Yen, T.T.; Allan, J.A.; Pearson, D.V.; Acton, J.M. (1977) Prevention of obesity in Avy/a mice by dehydroepiandrosterone. Lipids. 12:409-413.
Zumoff B; Strain GW; Kream J; O'Connor J; Rosenfeld RS; Levin J; Fukushima DK (1982) Age variation of the 24-hour mean plasma concentrations of androgens, estrogens, and gonadotropins in normal adult men. J.Clin.Endocrinol.Metab. 54:534-538.
Rote Liste, Bundesverba
Cebulak Mary C.
Dees Jos,e G.
Endorecherche Inc.
LandOfFree
Therapeutic methods and delivery systems utilizing sex steroid p does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic methods and delivery systems utilizing sex steroid p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic methods and delivery systems utilizing sex steroid p will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-884616